MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers

Stock Information for AIM ImmunoTech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About AIM ImmunoTech Inc.

MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
MediWound to Report First Quarter 2025 Financial Results
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
MediWound to Report Fourth Quarter and Full Year 2024 Financial Results
MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care
MediWound to Present at the 45th Annual TD Cowen Health Care Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.